



IFW

MAIL STOP - PCT  
Attorney Docket No.: 27391U

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Art Unit: Unknown  
BRUECK-SCHEFFLER, Antje Examiner: Unknown  
Application No.: 10/582,499  
Filed: June 9, 2006  
Intl. Application No.: PCT/EP2004/053495  
Intl. Filing Date: December 15, 2004  
Title: **AQUEOUS SUSPENSIONS OF CICLSONIDE FOR NEBULISATION**

**TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:


- 1) Information Disclosure Statement;
- 2) PTO Form-1449 with 53 cited references, and copies of 33 of the 53 cited references.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

September 11, 2006

By:

  
Gary M. Nath, Reg. No. 26,965  
Sheldon M. McGee, Reg. No. 50,454  
Customer No. 34375

1e



MAIL STOP - PCT  
Attorney Docket No.: 27391U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Art Unit: Unknown  
BRUECK-SCHEFFLER, Antje Examiner: Unknown  
Application No.: 10/582,499  
Filed: June 9, 2006  
Intl. Application No.: PCT/EP2004/053495  
Intl. Filing Date: December 15, 2004  
Title: **AQUEOUS SUSPENSIONS OF CICLSONIDE FOR NEBULISATION**

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

- a. ☐ [XXX] The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- b. ☐ [ ] The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.  
The enclosed statement is accompanied by [check one]:  
☐ [ ] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or  
☐ [ ] ii. a check in the amount required by 37 C.F.R. 1.17(p).
- c. ☐ [ ] The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113,

or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

☐ Certification report(e) below; and

☐ a check in the amount as required by 1.17(p).

d. ☐ The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

☐ I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

☐ Appropriate certification is attached.

f. [XXX] If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

g. [XXX] Copies of the documents are attached herewith with a completed PTO Form-1449.

[ ] or  
Copies of the documents are not attached, with a completed PTO Form-1449 as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

[XXX] and / or  
Copies of US Patents/Publications not attached, with a completed PTO Form-1449 as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.


The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

September 11, 2006

By:

  
Gary M. Nath, Reg. No. 26,965  
Sheldon M. McGee, Reg. No. 50,454  
Customer No. 34375

1e



**FORM PTO-1449**  
**INFORMATION DISCLOSURE**  
**CITATION**

In re Application of:  
BRUECK-SCHEFFLER, Antje

Application No:  
10/582,499

Art Unit:  
Unknown

Filed: June 9, 2006

Examiner: Unknown

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Issue / Publication Date	Inventor	Filed
	A1	2005/0245493	11/3/2005	Marx et al.	8/29/2003
	A2	2003/0103864	6/5/2003	McAffer et al.	9/30/2002
	A3	5,346,702	9/13/1994	Na et al.	12/4/1992
	A4	6,392,036 (corresponds to WO99/25359)	5/21/2002	Karlsson et al.	11/11/1998
	A5	5,858,410 (corresponds to WO96/14830)	1/12/1999	Muller et al.	11/9/1995
	A6	5,482,934	1/9/1996	Calatayud et al.	7/20/1994
	A7	6,120,752	9/19/2000	Oliver et al.	5/13/1998
	A8	6,264,923	7/24/2001	Oliver et al.	11/15/1999
	A9	5,540,930	7/30/1996	Guy et al.	10/25/1993
	A10	6,667,344	12/23/2003	Banerjee et al.	6/22/2001
	A11	2005/0009923	1/13/2005	Banerjee et al.	7/9/2004
	A12	6,598,603	7/29/2003	Andersson et al.	12/23/1998
	A13	6,464,958 (corresponds to WO00/25746)	10/15/2002	Bernini et al.	10/28/1999
	A14	5,747,061	5/5/1998	Amselem et al.	7/29/1996
	A15	4,787,536	11/29/1988	Widerström	2/27/1986
	A16	2004/0023935	2/5/2004	Banerjee et al.	8/2/2002
	A17	5,733,901 (corresponds to WO94/22899)	3/31/1998	Gutterer	3/31/1994
	A18	6,939,559 (corresponds to WO99/53899)	9/6/2005	Nishibe et al.	4/21/1999
	A19	2005/0244339 A1 (corresponds to WO2005/037246)	11/3/2005	Jauernig et al.	4/14/2005
	A20	6,967,017 (corresponds to WO01/07014)	11/22/2005	Malvolti et al.	7/20/2000

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document Number	Publication Date	Country	Translation
	A21	01/28562 A1	4/26/2001	WO	N/A
	A22	99/25359 A1	5/27/1999	WO	N/A
	A23	01/28563 A1	4/26/2001	WO	N/A
	A24	2004/085460 A1	10/7/2004	WO	N/A
	A25	02/083113 A2	10/24/2002	WO	N/A
	A26	2004/035441	2/5/2004	JP	Abstract
	A27	1 079 808 B1	3/7/2001	EP	N/A
	A28	101 45 361 A1	4/3/2003	DE	Abstract
	A29	2004/032980 A1	4/22/2004	WO	N/A

Examiner

Date Considered

**FORM PTO-1449**  
**INFORMATION DISCLOSURE**  
**CITATION**

In re Application of:  
BRUECK-SCHEFFLER, Antje

Application No:  
10/582,499

Application No:  
10/582,499

Filed: June 9, 2006

Filed: June 9, 2006

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Document Number	Publication Date	Country	Translation
	A30 2004/004739 A1	1/15/2004	WO	N/A
	A31 03/086347 A1	10/23/2003	WO	N/A
	A32 00/25746 A2	5/11/2000	WO	N/A
	A33 2004/078102 A2	9/16/2004	WO	N/A
	A34 98/09982 A1	3/12/1998	WO	N/A
	A35 94/22899 A1	10/13/1994	WO	Abstract
	A36 2005/115332 A2	12/8/2005	WO	N/A
	A37 2004/054545 A1	7/1/2004	WO	N/A
	A38 95/31964 A1	11/30/1995	WO	N/A
	A39 03/070285 A1	8/28/2003	WO	N/A
	A40 99/53899 A1	10/28/1999	WO	Abstract
	A41 01/28517 A1	4/26/2001	WO	Abstract
	A42 1 632 250 A1	3/8/2006	EP	N/A
	A43 1 574 222 A1	9/14/2005	EP	N/A
	A44 2005/037246 A2	4/28/2005	WO	Abstract
	A45 03/086347 A1	10/23/2003	WO	N/A
	A46 03/035030 A1	5/1/2003	WO	N/A
	A47 2006/055632 A2	5/26/2006	WO	N/A

**OTHER**

Examiner Initial	(Including Author, Title, Date, Pertinent Pages, etc.)
A48	European Pharmacopoeia, Vol. 5.0, Chapter 2.6.1. on Sterility, p. 145-149, (2005).
A49	Dent, G., "Ciclesonide", <u>Current Opinion Investig Drugs</u> , Vol. 3, No. 1, p. 78-83, (2002).
A50	Illum, L., et al., "Surface area stability of micronized steroids sterilized by irradiation", <u>Arch. Pharm. Chemi Sci. Ed.</u> , Vol. 2, p. 167-174, (1974).
A51	European Pharmacopoeia, Vol. 5.0, Chapter 5.1.1. on Methods of Preparation of Sterile Products, p. 445-447, (2005).
A52	US Pharmacopoeia, Vol. 26, Chapter 1211 on Sterilization and Sterility Assurance of Compendial Articles", p. 2433-2439.

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449</b>  <b><u>INFORMATION DISCLOSURE</u></b> <b><u>CITATION</u></b>		In re Application of: BRUECK-SCHEFFLER, Antje	
		Application No: 10/582,499	Application No: 10/582,499
		Filed: June 9, 2006	Filed: June 9, 2006
OTHER			
Examiner Initial		(Including Author, Title, Date, Pertinent Pages, etc.)	
	A53	US Pharmacopoeia, Vol. 26, Chapter 71 on Sterility Tests", p. 2011-2016.	
	A54		
	A55		
	A56		
	A57		
	A58		
	A59		
	A60		
	A61		
	A62		
	A63		
	A64		
	A65		
	A66		
	A67		
	A68		
	A69		
Examiner		Date Considered	
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</small>			